期刊文献+

慢性淋巴细胞白血病患者外周血p53基因突变观察 被引量:2

p53 gene mutation in chronic lymphocytic leukemia patients′ peripheral blood
下载PDF
导出
摘要 目的观察慢性淋巴细胞白血病(CLL)患者外周血中p53基因突变情况,并探讨其临床意义。方法采用PCR联合测序技术检测80例CLL患者及10例健康体检者外周血中的p53基因,CLL患者中25例应用FC方案(氟达拉滨25 mg/m2,环磷酰胺250 mg/m2,第1~3天静滴)化疗,28 d为1个疗程,治疗2~6个疗程。结果 80例CLL患者中12例(15.0%)检测到p53基因突变,其中错义突变11例、无义突变1例,未检测到插入和缺失;突变位点均发生在外显子(exon)5~9,其中发生在exon 5 2例、exon 6 3例、exon 7 1例、exon 8 5例、exon 9 1例,exon2~4、exon 10、exon 11未检测到突变。健康体检者中均未检测到p53基因突变。二者p53基因突变率比较,P<0.05。p53基因突变与Binet分期、p53基因缺失、IgVH突变有关(P均<0.05)。80例CLL患者中25例化疗后CR5例、PR 11例,总反应率(OR)为64.0%;p53基因突变者OR为14.3%,低于p53基因无突变者的83.3%(P<0.05)。结论 CLL患者外周血中存在p53基因突变,其可作为预后判定的指标。 Objective To investigate the mutation of p53 and its clinical significance in peripheral blood of patients with chronic lymphocytic leukemia (CLL). Methods p53 gene mutations were detected by polymerase chain reaction (PCR) and subsequent sequencing in peripheral blood of 80 CLL patients and 10 healthy controls. FC regimens (fludara- bine 25 mg/m2, cyclophosphamide 250 mg/m2, intravenous infusion for 3 days) were repeated for 2 to 6 cycles at four weeks intervals were administrated in 25 patients. Results Among 80 patients, 12 ( 15.0% ) cases had p53 mutations,including 11 cases of missense mutations and 1 case of nonsense mutation. No insertions or insertions were detected. Mutations were discovered in exon 5 to 9, including 2 cases of exon 5, 3 cases of exon 6, 1 case of exon 7, 5 cases of exon 8 and 1 case of exon 9. No mutations were detected in 10 healthy controlsor the remaining exons in CLL patients ( all P 〈 0.05 ). Patients with p53 mutations displayed higher incidence of advanced stage, p53 deletions, and unmutated IgVH ( all P 〈 0.05). In 25 patients treated with FC regimens, 5 cases achieved CR and 11 cases obtained PR (OR, overall response 64.0% ). Pa- tients with p53 mutations showed lower incidence of overall response than patients without mutations ( 14.3% vs 83.3%, P 〈0. 05). Conclusions p53 mutations occur in peripheral blood of patients with CLL. Our data confirm a role for p53 mutations as an important prognostic indicator in CLL.
出处 《山东医药》 CAS 2012年第34期1-4,共4页 Shandong Medical Journal
基金 国家自然科学基金资助项目(81170489) 江苏省自然科学基金资助项目(BK2010287)
关键词 P53基因 基因突变 慢性淋巴细胞白血病 p53 gene mutation chronic lymphocytic leukemia
  • 相关文献

参考文献17

  • 1Chiorazzi N, Rai KR, Ferrarini M, et al. Chronic lymphocytic leukemia[J]. N Engl J Med, 2005, 352(2) : 804-815. 被引量:1
  • 2张之南,沈悌主编..血液病诊断及疗效标准 第3版[M].北京:科学出版社,2007:271.
  • 3International workshop on chronic lymphocytic leukemia. Chronic lymphocytic leukemia : reeommendations for diagnosis, staging, and response eriteria [ J ]. Ann Intern Med, 1989,110 (3) : 236-238. 被引量:1
  • 4郑文娟,陈丽娟,吴雨洁,李丽,徐卫,李建勇.应用多重PCR技术检测慢性淋巴细胞白血病IgVH基因突变[J].中国实验血液学杂志,2006,14(6):1101-1104. 被引量:8
  • 5Vousden KH, Lu X. Live or let die: the cell's response to p53[J]. Nat Rev Cancer, 2002,2(8 ) :594-604. 被引量:1
  • 6Chipuk JE, Green DR. Dissecting p53-dependent apoptosis [J]. Cell Death Differ, 2006,13(6) :994-1002. 被引量:1
  • 7De Vries A, Flores ER, Miranda B, et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function [J]. Proc Natl Acad Sci, 2002,99 (5) :2948-2953. 被引量:1
  • 8Walker DR, Bond JP, Tarone RE, et al. Evolutionary conservation and somatic mutation hotspot maps of p53 : correlation with p.53 protein structural and functional features [ J ]. Oncogene, 1999, 18 (1) :211-218. 被引量:1
  • 9Trbusek M, Malcikova J, Smardova J, et al. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation sta- tus and previous treatment [J]. Leukemia, 2006,20 ( 6 ) : 1159-1161. 被引量:1
  • 10Sturm I, Bosanquet AG, Hermann S, et al. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA damaging chemotherapy[J]. Cell Death Differ, 2003,10(4) :477-484. 被引量:1

二级参考文献10

  • 1Shanafelt TD,Geyer SM,Kay NE.Prognosis at diagnosis:integrating molecular biologic insights into clinical practice for patients with CLL.Blood,2004;103:1202-1210 被引量:1
  • 2Chiorazzi N,Rai KR,Ferrarini M.Chronic lymphocytic leukemia.N Engl J Med,2005;352:804-815 被引量:1
  • 3Hamblin TJ,Davis Z,Gardiner A,et al.Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.Blood,1999;94:1848-1854 被引量:1
  • 4Damle RN,Wasil T,Fais F,et al.Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.Blood,1999;94:1840-1847 被引量:1
  • 5Montillo M,Hamblin T,Hallek M,et al.Chronic lymphocytic leukemia:novel prognostic factors and their relevance for risk-adapted therapeutic strategies.Haematologica,2005;90:391-399 被引量:1
  • 6van Dongen JJM,Langerak AW,Bruggemann M,et al.Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations:Report of the BIOMED-2 Concerted Action BMH4-CT98-3936.Leukemia,2003;17:2257-2317 被引量:1
  • 7Tobin G,Thunberg U,Johnson A,et al.Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia.Blood,2002;99:2262-2264 被引量:1
  • 8Matthews C,Catherwood M,Morris TC,et al.Routine analysis of IgVH mutational status in CLL patients using BIOMED-2 standardized primers and protocols.Leuk Lymphoma,2004; 45:1899-1904 被引量:1
  • 9van't Veer MB,Brooijmans AM,Langerak AW,et al.The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia.Haematologica,2006;91:56-63 被引量:1
  • 10陈丽娟.慢性淋巴细胞白血病IgV(H)基因突变研究进展[J].国外医学(输血及血液学分册),2003,26(3):250-251. 被引量:2

共引文献7

同被引文献18

  • 1Vousden K H,LU X. Live or let die:the cell's response to p53[J]. Nat Rev Cancer, 2002,2(8) : 594-604. 被引量:1
  • 2Chipuk J E, Green D R. Dissecting p53-dependent apoptosis[J]. Cell Death Differ, 2006,13(6) : 994-1002. 被引量:1
  • 3De Vries A,Flores E R,Miranda B,et al. Targeted point muta tions of p53 lead to dominant-negative inhibition of wild-type p53 funetion[J]. Proe Natl Acad Sei U S A,2002,99(5) ..2948- 2953. 被引量:1
  • 4Walker D R,Bond J P,Tarone R E,et al. Evolutionary conser- vation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features[J]. Oneo- gene, 1999,18(1) :211-218. 被引量:1
  • 5Melo M B,Ahmad N N,Lima C S,et al. Mutations in the p53 gene in acute myeloid leukemia patients correlate with poor prognosis[J]. Hematology, 2002,7 (1): 13-19. 被引量:1
  • 6Pavlova S, Mayer J, Koukalova H, et al. High frequency of tempera- ture-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast [J]. Int J Oncol, 2003,23(1):121-131. 被引量:1
  • 7Nakano Y, Naoe T, Kiyoi H, et al. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia[J]. Eur J Haematol,2000,65(1) :23-31. 被引量:1
  • 8Chiaretti S, Brugnoletti F, Tavolaro S, et al. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases nega- tive for recurrent fusion genes and correlate with poor re- sponse to induction therapy[J]. Haematologica, 2013,98 ( 5 ) : e59-e61. 被引量:1
  • 9Vousden KH, Lu X. Live or let die: the cell' s response to p53 [J]. Nat Rev Cancer, 2002,2(8) :594-604. 被引量:1
  • 10Chipuk JE, Green DR. Dissecting p53-dependent apoptosis[ J]. Cell Death Differ, 2006,13 (6) :994-1002. 被引量:1

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部